^
BIOMARKER:

HER-2 amplification + PD-L1 expression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
10d
Current approach to the management of newly diagnosed metastatic gastric, GEJ or esophageal cancer Design, eligibility criteria and primary findings from the Phase III KEYNOTE-590 study leading to the recent FDA approval of pembrolizumab combined with chemotherapy for patients with advanced esophageal or GEJ carcinoma who are not candidates for surgical resection or definitive chemoradiation; role in clinical practice Available efficacy and safety results from Phase III CheckMate 649 trial supporting the recent FDA approval of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma Similarities and differences between the designs, entry criteria and key efficacy and safety outcomes of the Phase III CheckMate 649 and ATTRACTION-4 trials of first-line nivolumab/chemotherapy for advanced gastric/GEJ adenocarcinoma; clinical role of PD-L1 expression levels and implications for clinical practice Available efficacy and safety outcomes from the Phase III CheckMate 577 study leading to the recent FDA approval of nivolumab for patients with completely resected esophageal or GEJ cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy; incorporation into current treatment algorithms Clinical and biologic factors affecting the choice of therapy for patients with advanced esophageal cancer; impact of histology on the selection and sequencing of therapy Current role of anti-PD-1 monotherapy in patients with relapsed or refractory esophageal cancer Frequency of HER2 amplification and mutations in HER2-positive gastric or GEJ cancer; historical management of patients with HER2-positive disease Key efficacy and safety findings supporting the recent FDA approval of pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma (KEYNOTE-811); integration into current clinical management Available data from the Phase II DESTINY-Gastric01 trial of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen; recent FDA approval and optimal integration into current clinical practice Spectrum, incidence and severity of toxicities, including interstitial lung disease (ILD), with T-DXd in the DESTINY-Gastric01 trial Design, eligibility criteria and key endpoints of the ongoing Phase III DESTINY-Gastric04 trial comparing T-DXd to ramucirumab/paclitaxel for patients with HER2-positive metastatic and/or unresectable gastric or GEJ adenocarcinoma who have progressed on or after a trastuzumab-containing regimen Other ongoing evaluations of T-DXd in patients with HER2-amplified or mutation-positive advanced gastric/GEJ cancer (eg, DESTINY-Gastric03, DPT01) Available data with and current role of anti-PD-1/PD-L1 antibodies for patients with locally advanced or metastatic gastric or GEJ cancer; impact of PD-L1 CPS on the utilization and sequencing of immune checkpoint inhibitors Biologic rationale for and ongoing investigations of anti-PD-1/PD-L1 antibodies in combination with chemotherapy, targeted therapy and/or other immunotherapies in gastric, GEJ and esophageal cancer (eg, KEYNOTE-859, KEYNOTE-585, RiME, INTEGRATEIIb) Optimal integration of ramucirumab into current clinical algorithms; other ongoing investigations of ramucirumab-containing combination regimens (eg, RAMIRIS, RAMSES/FLOT7)
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 amplification + PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
26d
PD-L1 positivity was seen in cases with advanced pathological features, which suggest its role in the tumorigenesis of gastric and gastroesophageal junction adenocarcinoma. Her2neu positivity showed no correlation with advanced pathological features as well as no prognostic significance, which could be attributed to tumor heterogeneity, endoscopic nature of the biopsies, and non-confirmation of equivocal cases by fluorescent in situ hybridization.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
|
PD-L1 expression • TP53 mutation • HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 expression • PD-L1 amplification • HER-2 amplification + PD-L1 expression
2ms
We discovered some driver genes mutations which potentially sensitive to the corresponding targeted drugs in Chinese R/R WT patients . Large sample size was needed to provide a better understanding of molecular features in R/R WT patients to achieve precision medicine.
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • MSI (Microsatellite instability) • NF1 (Neurofibromin 1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDK4 (Cyclin-dependent kinase 4) • MDM4 (The mouse double minute 4) • FANCA (FA Complementation Group A) • CHEK2 (Checkpoint kinase 2) • AMER1 (APC Membrane Recruitment Protein 1)
|
PD-L1 expression • EGFR mutation • HER-2 amplification • MET amplification • FGFR1 amplification • PD-L1 negative • CHEK2 mutation • FANCA mutation • HER-2 amplification + PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
2ms
This is the first study comprehensively investigating the molecular landscape of PDACs according to CXCR4 RNA expression . High CXCR4 expression is associated with an improved survival and a pro-inflammatory phenotype that may identify a subset of tumors with greater responsiveness to immunotherapeutic approaches.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • GNAS (GNAS Complex Locus) • TNFRSF14 (TNF Receptor Superfamily Member 14)
|
PD-L1 expression • HER-2 amplification • HER-2 amplification + PD-L1 expression
|
MI Tumor Seek™
3ms
Taken together, the strategy of co-targeting HER2 and WEE1 could overcome resistance to trastuzumab in HER2-positive cancers, supporting further clinical development in HER2-positive cancer patients.
Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • CD163 (CD163 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 amplification + PD-L1 expression • EGFR positive
|
Herceptin (trastuzumab) • adavosertib (AZD1775)
3ms
c-MET was found to be an independent prognostic factor for DFS of GC patients. A combination of c-MET inhibitors and PD1 antibodies could enhance the killing capacity of T cells, providing a preliminary basis for the clinical research on the same combination in GC treatment.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 negative • MET amplification • MET expression • HER-2 amplification + PD-L1 expression
3ms
We analyzed the distribution of microsatellite status, PD-L1 expression and TMB in Chinese patients with GAC. Interestingly, our data showed that mutated ACVR2A was significantly associated with MSI-H and TMB-H. In addition, approximately 8% of patients were identified harboring hyperprogression-related gene alterations.
Clinical • Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • MDM2 (E3 ubiquitin protein ligase) • MDM4 (The mouse double minute 4) • ACVR2A (Activin A Receptor Type 2A)
|
PD-L1 expression • TMB-H • HER-2 amplification • MSI-H/dMMR • HER-2 amplification + PD-L1 expression
3ms
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • HER-2 amplification • HER-2 amplification + PD-L1 expression
|
Tecentriq (atezolizumab) • carboplatin • paclitaxel • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab) • epirubicin • cyclophosphamide intravenous
4ms
These agents include sotorasib (AMG 510), adagrasib (MRTX 849), and JNJ-74699157. In addition to testing for known actionable oncogenic driver alterations in EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, RET, and NTRK and for expression of PD-L1, pathologists, medical oncologists, and community practitioners will need to incorporate routine testing for emerging biomarkers such as MET amplification, ERBB2 (HER2), and KRAS mutations, particularly KRAS G12C, considering the promising development of direct inhibitors of KRAS protein.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • KRAS mutation • HER-2 amplification • KRAS G12C • MET amplification • HER-2 mutation • MET exon 14 mutation • KRAS G12 • HER-2 amplification + PD-L1 expression • RET expression • NTRK expression
|
Lumakras (sotorasib) • adagrasib (MRTX849) • JNJ-74699157
4ms
A subset of UCS with serous morphology have overexpression and/or amplification of HER2, which may predict response to HER2-targeted therapies. HER2-positive UCS may be less susceptible to immune checkpoint inhibition as they uncommonly show MMR deficiency and/or strong PD-L1 expression. Thus, HER2-targeted therapies could be of clinical utility in a subset of UCS without other adjuvant treatment options.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
|
PD-L1 expression • TP53 mutation • HER-2 positive • HER-2 amplification • HER-2 overexpression • HER-2 expression • TP53 expression • HER-2 amplification + PD-L1 expression
4ms
NTRK -R can occur in secretory, metaplastic and typical ductal MBC. NTRK1 -R cases seen in this cohort do not involve known transcription factors and thus their responsiveness to NTRK targeted therapy needs further clinical validation . One-third of NTRK3 -R involve fusions with the ETV6 transcription factor and are predominantly, but not exclusively found in secretory carcinomas.
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR1 (Fibroblast growth factor receptor 1) • MSI (Microsatellite instability) • NF1 (Neurofibromin 1) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • HER-2 amplification • NTRK1 fusion • NTRK2 fusion • HER-2 amplification + PD-L1 expression
|
FoundationOne® CDx • VENTANA PD-L1 (SP142) Assay
4ms
In this small series of SDC, biomarkers do not seem to correlate with disease biology, although they provide additional treatment options. SDC may harbor a different immune profile compared to other subtypes, with an indication of T-cell dysfunction.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • HER-2 amplification • HER-2 overexpression • AR splice variant 7 • HER-2 amplification + PD-L1 expression
6ms
Nevertheless, impact on patients’ survival needs to be further explored. A larger collection of cases is currently ongoing in the context of a multicenter trial and updated results will be presented at the meeting.
Tumor Mutational Burden • PD(L)-1 Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker • Next-generation sequencing
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • ARID1A (AT-rich interaction domain 1A) • FGFR (Fibroblast Growth Factor Receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • EGFR mutation • HER-2 amplification • MSI-H/dMMR • BRAF mutation • PIK3CA mutation • PTEN mutation • STK11 mutation • MET exon 14 mutation • MYC amplification • ALK fusion • RET mutation • RET rearrangement • MET mutation • ARID1A mutation • ALK translocation • EGFR negative • HER-2 amplification + PD-L1 expression
|
FoundationOne® CDx
6ms
Comprehensive genomic profiling elucidated that MTAP GA are frequent in IC and features relatively high GA/tumor, including 9p21 co-deletion, but relatively low TMB and PD-L1 expression. Isolated MTAP deletion without CDKN2A/B co-deletion was extremely rare. In addition to the potential targeting of PRMT5 in MTAP-IC tumors, co-altered genes known to be targets in IC such as FGFR2, IDH1 and BRAF are still prevalent in MTAP-IC, indicating potential for combining targeted therapies in some MTAP-IC patients.
Tumor Mutational Burden • PD(L)-1 Biomarker • PARP Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • SMAD4 (SMAD family member 4) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BRCA (Breast cancer early onset) • PRMT5 (Protein Arginine Methyltransferase 5)
|
PD-L1 expression • BRAF V600E • TP53 mutation • KRAS mutation • HER-2 amplification • MSI-H/dMMR • BRAF V600 • KRAS G12C • MET amplification • PD-L1 underexpression • CDKN2A deletion • TMB-L • PD-L1 negative • MTAP deletion • KRAS G12 • CDKN2B deletion • HER-2 amplification + PD-L1 expression • KRAS deletion • miR138 underexpression + miR497 overexpression
|
FoundationOne® CDx • PD-L1 IHC 22C3 pharmDx
8ms
The expression of the HER2 gene, PD-L1, and PD-1 in gastric cancer was correlated with the stage and lymph node metastasis of gastric cancer (P < 0.05). The combined detection of the HER2 gene and PD-1/PD-L1 in gastric cancer provides an important reference index for the prognosis of gastric cancer and the benefit of targeted antitumor drugs.
Journal • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • HER-2 amplification • HER-2 expression • HER-2 amplification + PD-L1 expression • PD-L1 expression + HER-2 overexpression
8ms
Tmab can upregulate PD-L1 expression on GC cells through interaction with NK cells. These results suggest clinical implications in the assessment of the predictive significance of PD-L1 expression for PD-1 inhibitors.
Journal • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 amplification • HER-2 amplification + PD-L1 expression
|
Herceptin (trastuzumab)
8ms
Almost two-thirds of breast cancer BrM expressed AR, while only 15% expressed PD-L1. HER2+ luminal B and HER2+ subtypes were most likely to be AR+. Meanwhile, PD-L1 expression was predominant in the triple negative subgroup.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • AR (Androgen receptor)
|
PD-L1 expression • HER-2 expression • AR expression • HER-2 amplification + PD-L1 expression
|
VENTANA PD-L1 (SP142) Assay
8ms
Despite several biomarkers used in the selection of treatment therapies, treatment outcomes remain poor. Future research efforts will focus on the identification of new biomarkers, moving existing biomarkers into earlier lines of therapy, and evaluating new combinations of existing biomarkers and therapies.
Review • Journal • MSi-H Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR (Fibroblast Growth Factor Receptor) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • HER-2 amplification • MSI-H/dMMR • HER-2 amplification + PD-L1 expression
9ms
"All other translocations, or discrepancy between IHC and FISH, require a sequencing-based confirmation procedure. The low frequency of NTRK fusions, and high sensitivity of NTRK-IHC, suggest using IHC as a prescreening tool with subsequent sequencing-based analysis for IHC positive cases."
Journal • Review
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • HER-2 amplification • ALK translocation • HER-2 amplification + PD-L1 expression • NTRK fusion
|
Vysis ALK Break Apart FISH Probe Kit
11ms
Clinical • New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ALB (Albumin)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • HER-2 amplification + PD-L1 expression • TMB + PD-L1 expression
|
AiRuiKa (camrelizumab)
11ms
Legal entity responsible for the study: Foundation Medicine Inc. Funding: Foundation Medicine Inc.
Tumor Mutational Burden • PD(L)-1 Biomarker • PARP Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • MSI (Microsatellite instability) • CCND1 (Cyclin D1) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • BRCA (Breast cancer early onset) • PRMT5 (Protein Arginine Methyltransferase 5)
|
PD-L1 expression • TMB-H • HER-2 amplification • MSI-H/dMMR • PD-L1 overexpression • KRAS G12C • CDKN2A deletion • KRAS G12 • HER-2 amplification + PD-L1 expression • BRAF amplification • CDKN2A deletion + MTAP deletion • TMB + PD-L1 expression
|
FoundationOne® CDx • PD-L1 IHC 22C3 pharmDx
1year
In 2017 there was progression in retroperitoneal and mesenteric LN , with partial remission post-gemcitabine/nab-paclitaxel and asymptomatic progression after 4 months, non-responsive to stereotactic radiosurgery...The patient received 16 doses of nivolumab since March 2019... The “immunogenic ”PDA may represent a biomarker of response to immune-enhancing treatment strategies as shown by our case. Studies with larger patient numbers with a similar pattern of immune-reaction are required to further substantiate this observation.
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CD8 (cluster of differentiation 8) • PALB2 (Partner and localizer of BRCA2)
|
PD-L1 expression • HER-2 amplification • PALB2 mutation • KIT mutation • PD-L1 negative • ERBB3 mutation • PD-L1 amplification • BLM mutation • HER-2 amplification + PD-L1 expression
|
Opdivo (nivolumab) • gemcitabine • Abraxane (albumin-bound paclitaxel)
over1year
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • HER-2 amplification • HER-2 amplification + PD-L1 expression
|
Tecentriq (atezolizumab) • carboplatin • paclitaxel • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab) • epirubicin • cyclophosphamide intravenous
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our